- Conditions
- Eosinophilic Asthma
- Interventions
- ICS-LABA, benralizumab, Placebo for Benralizumab
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
- Conditions
- Asthma
- Interventions
- Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 36
- States / cities
- Centreville, Alabama • Little Rock, Arkansas • Newport Beach, California + 31 more
- Conditions
- Asthma
- Interventions
- Tezepelumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
- Conditions
- Egg Allergy, Eligible for Vaccination Against Influenza
- Interventions
- FluMist intranasal influenza vaccine, Intramuscular influenza injection ("flu shot")
- Biological
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 6 Months and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 27,190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Asthma in Children, Nonadherence, Medication
- Interventions
- Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more
- Conditions
- Asthma
- Interventions
- Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Asthma
- Interventions
- tiotropium, long-acting β2-agonists (LABA), inhaled corticosteroids (ICS)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Asthma
- Interventions
- Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 50
- States / cities
- Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Chronic Obstructive Pulmonary Disease COPD
- Interventions
- AZD7624 1.0 mg, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Torrance, California • Denver, Colorado + 17 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Tozorakimab 1, Tozorakimab 2, Placebo
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 1,713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 46
- States / cities
- Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more
- Conditions
- Asthma
- Interventions
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- COPD
- Interventions
- Ensifentrine 3 mg twice daily
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Asthma
- Interventions
- Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 7,857 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 8
- States / cities
- DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
- Conditions
- Asthma
- Interventions
- FF/UMEC/VI, ELLIPTA, FF/VI
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 50
- States / cities
- Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Interventions
- Targeted Lung Denervation (TLD)
- Device
- Lead sponsor
- Nuvaira, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Detroit, Michigan + 7 more